AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies
OCALA, FL / ACCESSWIRE / February 5, 2020 / AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the...